IOTA Pharmaceuticals


IOTA Pharmaceuticals
Fragment - based Drug Discovery
GBM Drug Bank
Glioma & Glioblastoma
WINDOW on Glioblastoma
IOTA Pharmaceuticals
June 15, 2016

IOTA scientists publish paper on use of biosensor technology in PDE inhibitor binding characterization
A paper by IOTA scientists Anitha Shanmugham and Paul England and VU collaborators, describing the use of surface plasmon resonance (SPR) based assays to characterize the interaction between therapeutically relevant phosphodiesterases and small molecules, has been published in Analytical Biochemistry. Entitled “Surface plasmon resonance biosensor assay for the analysis of small-molecule inhibitor binding to human and parasitic phosphodiesterases”, the paper discusses the applications of surface plasmon resonance biosensor assays to determine the binding kinetics of small molecule inhibitors to T.brucei PDEB1 and human PDE4, as well as the efficacy and relative specificity of drug leads. The assay shows promise for the development of a target-fragment interaction platform to explore potential drug leads.